Financial Results for the fourth quarter and year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Smruthi Organics reported FY25 revenue of Rs 12,609.67 lakhs, a marginal decline from Rs 12,771.86 lakhs in FY24. Net profit was Rs 356.29 lakhs versus Rs 359.03 lakhs, giving EPS of Rs 3.11 (vs Rs 3.14). Q4 FY25 revenue came in at Rs 3,817.01 lakhs with net profit of Rs 223.01 lakhs. The Formulation segment swung to a profit of Rs 73 lakhs from a Rs 237 lakh loss last year, while the core API segment's pre-tax profit eased to Rs 912 lakhs from Rs 999 lakhs. Statutory auditor Gokhale & Sathe issued an unmodified (clean) opinion on the results. The Board has recommended a dividend of Rs 1.5 per share (15%) on equity capital of Rs 11.45 crore, subject to shareholder approval.
A steady, no-surprise full-year performance with a clean audit and a modest dividend should reassure existing shareholders. Investors may note the slight year-on-year revenue dip and a sharp ~44% increase in total borrowings, though the overall debt-to-equity ratio stays comfortable and operating cash flow remains healthy at nearly Rs 10 crore.